Amendment 839 took effect November 1, 2026
Amendment 839 is now part of the 2026 Federal Sentencing Guidelines Manual. It responds to the HALT Fentanyl Act, which permanently placed the statutory class of fentanyl-related substances in Schedule I and added that class to the federal trafficking penalty provisions.
The amendment is immediately relevant in federal sentencings involving a substance that meets the definition in 21 U.S.C. § 812(e). It does not mean every fentanyl-related compound produces the same final sentence, and it does not itself reopen a sentence that became final under an earlier manual.
The Drug Quantity Table now presumptively treats the class like fentanyl analogues
Section 2D1.1 now lists fentanyl-related substances at the same quantity thresholds and base offense levels as fentanyl analogues. The amendment also assigns one gram of a fentanyl-related substance a converted drug weight of 10 kilograms for the equivalency table.
That starting point follows the HALT Fentanyl Act's statutory treatment of the class. Under 21 U.S.C. § 841(b)(1), 100 grams of a fentanyl-related substance can trigger the ten-year minimum tier and 10 grams can trigger the five-year minimum tier, subject to the statute's other requirements. The statutory minimum and the advisory guideline calculation remain separate questions.
A defendant may rebut the presumptive guideline treatment in two defined circumstances
New Note (K) to the Drug Quantity Table creates a rebuttable presumption that the fentanyl-related-substance levels apply. The defendant may overcome that presumption by establishing either that the substance functions to block, diminish, or counteract the effect produced by fentanyl or a fentanyl analogue, or that the substance is significantly less potent than fentanyl.
If either showing is made, the court should calculate the base offense level using the converted drug weight of the most closely related controlled substance under Application Note 6. The Commission describes this as a safety valve, but it is a narrow guideline calculation rule—not the statutory safety valve in 18 U.S.C. § 3553(f).
Chemical classification alone does not establish the rebuttal
The statutory definition is class-based and turns on specified structural relationships to fentanyl. Amendment 839 recognizes that structural breadth may include substances whose pharmacological effects or potency differ materially from fentanyl.
A useful record may require laboratory identification, purity and mixture evidence, pharmacology or toxicology material, expert analysis, validated potency comparisons, chain-of-custody information, and careful identification of the proposed most closely related controlled substance. A name, chemical diagram, or unsupported assertion that a compound is weaker will not necessarily carry the defendant's burden.
The marketing enhancement follows the same gateway
Amendment 839 also adds fentanyl-related substances to the §2D1.1 enhancement for representing or marketing covered fentanyl substances as another substance or as a legitimately manufactured drug. For a fentanyl-related substance, however, the enhancement applies only when the court uses the Drug Quantity Table offense level specified for fentanyl, a fentanyl analogue, or a fentanyl-related substance.
That proviso matters when the defendant successfully rebuts the presumptive table treatment. The base-offense-level evidence and the enhancement analysis should be addressed together rather than assumed from the statutory label alone.
The HALT Fentanyl Act's mandatory minimums are not displaced by the guideline rebuttal
The rebuttal rule changes how the advisory guideline base offense level is determined. It does not amend the statutory definition in § 812(e), erase an element of conviction, or reduce a mandatory minimum established by § 841 or § 960.
A case may therefore involve a successfully rebutted guideline presumption while still presenting a statutory minimum issue. Eligibility for relief from a mandatory minimum requires its own legal basis, such as the statutory safety valve when every requirement is satisfied or a qualifying government motion.
The applicable manual and ex post facto rules still control
Section 1B1.11 generally directs the sentencing court to use the manual in effect on the sentencing date. If using the current manual would create an ex post facto problem by increasing the applicable range for earlier conduct, the court uses the manual in effect when the offense of conviction was committed.
The manual ordinarily must be applied as an integrated whole. Pending sentencings, remands, continuing offenses, and multiple-count cases require a complete manual analysis; a party cannot simply combine the new potency rebuttal with unrelated provisions from a different edition.
Amendment 839 is not a new § 3582(c)(2) reopening mechanism
A final federal sentence may be reduced under § 3582(c)(2) only when the Sentencing Commission has made the relevant guideline amendment retroactive through §1B1.10. Amendment 839 is not included in the covered-amendments list.
The fact that a compound might receive a different base offense level under the new evidentiary rule does not by itself authorize a court to modify a final judgment. A final case must identify a separate procedural vehicle and satisfy that vehicle's custody, timing, exhaustion, successive-motion, and jurisdictional requirements.
The record should separate identity, potency, quantity, and finality
A responsible review should collect the laboratory reports and underlying data, expert materials, discovery concerning the substance, indictment, plea or verdict, presentence report, objections, sentencing transcript, guideline worksheets, statement of reasons, judgment, offense dates, prior manual, appeal history, and any later collateral filings. It should then distinguish four questions: what the substance is, what it does, how much is attributable, and whether the court has authority to act now.
This article provides general educational information, not legal advice, an eligibility determination, or a prediction of relief. Substance identity, pharmacology, the defendant's burden, statutory penalties, the applicable manual, and the case's procedural posture require individualized review.